Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Warner-Lambert discontinues Rezulin sales

At FDA's request, WLA discontinued sales of its Rezulin troglitazone to treat Type II diabetes. WLA

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE